Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Anthranilic amide and imidazobenzothiadiazole compounds disrupt Mycobacterium tuberculosis membrane potential.

Smith J, Wescott H, Early J, Mullen S, Guzman J, Odingo J, Lamar J, Parish T.

Medchemcomm. 2019 May 3;10(6):934-945. doi: 10.1039/c9md00088g. eCollection 2019 Jun 1.

PMID:
31303991
2.

Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections.

Washburn A, Abdeen S, Ovechkina Y, Ray AM, Stevens M, Chitre S, Sivinski J, Park Y, Johnson J, Hoang QQ, Chapman E, Parish T, Johnson SM.

Bioorg Med Chem Lett. 2019 Jul 1;29(13):1665-1672. doi: 10.1016/j.bmcl.2019.04.034. Epub 2019 Apr 24.

PMID:
31047750
3.

Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase.

Crespo RA, Dang Q, Zhou NE, Guthrie LM, Snavely TC, Dong W, Loesch KA, Suzuki T, You L, Wang W, O'Malley T, Parish T, Olsen DB, Sacchettini JC.

J Med Chem. 2019 May 9;62(9):4483-4499. doi: 10.1021/acs.jmedchem.9b00020. Epub 2019 Apr 19.

4.

Characterization of MenA (isoprenyl diphosphate:1,4-dihydroxy-2-naphthoate isoprenyltransferase) from Mycobacterium tuberculosis.

Dhiman RK, Pujari V, Kincaid JM, Ikeh MA, Parish T, Crick DC.

PLoS One. 2019 Apr 12;14(4):e0214958. doi: 10.1371/journal.pone.0214958. eCollection 2019.

5.

Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors.

Berube BJ, Russell D, Castro L, Choi SR, Narayanasamy P, Parish T.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02661-18. doi: 10.1128/AAC.02661-18. Print 2019 Jun.

6.

8-Hydroxyquinolines are bactericidal against Mycobacterium tuberculosis.

Odingo JO, Early JV, Smith J, Johnson J, Bailey MA, Files M, Guzman J, Ollinger J, Korkegian A, Kumar A, Ovechkina Y, Parish T.

Drug Dev Res. 2019 Mar 20. doi: 10.1002/ddr.21531. [Epub ahead of print]

PMID:
30893501
7.

The relevance of persisters in tuberculosis drug discovery.

Mandal S, Njikan S, Kumar A, Early JV, Parish T.

Microbiology. 2019 May;165(5):492-499. doi: 10.1099/mic.0.000760. Epub 2019 Feb 18.

PMID:
30775961
8.

Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.

Robertson GT, Ektnitphong VA, Scherman MS, McNeil MB, Dennison D, Korkegian A, Smith AJ, Halladay J, Carter DS, Xia Y, Zhou Y, Choi W, Berry PW, Mao W, Hernandez V, Alley MRK, Parish T, Lenaerts AJ.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02071-18. doi: 10.1128/AAC.02071-18. Print 2019 Apr.

9.

A high-throughput whole cell screen to identify inhibitors of Mycobacterium tuberculosis.

Ollinger J, Kumar A, Roberts DM, Bailey MA, Casey A, Parish T.

PLoS One. 2019 Jan 16;14(1):e0205479. doi: 10.1371/journal.pone.0205479. eCollection 2019.

10.

Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis.

Early J, Ollinger J, Darby C, Alling T, Mullen S, Casey A, Gold B, Ochoada J, Wiernicki T, Masquelin T, Nathan C, Hipskind PA, Parish T.

ACS Infect Dis. 2019 Feb 8;5(2):272-280. doi: 10.1021/acsinfecdis.8b00256. Epub 2018 Dec 17.

11.

DORA Editorial.

Parish T, Harris M, Fry N, Mathee K, Trujillo ME, Bentley S, Thomson N.

Microbiology. 2019 Feb;165(2):125-126. doi: 10.1099/mic.0.000751. Epub 2018 Dec 5. No abstract available.

PMID:
30516468
12.

DORA Editorial.

Parish T, Harris M, Fry N, Mathee K, Trujillo ME, Bentley S, Thomson N.

J Gen Virol. 2019 Jan;100(1):1-2. doi: 10.1099/jgv.0.001191. Epub 2018 Dec 5. No abstract available.

PMID:
30516467
13.

DORA Editorial.

Parish T, Harris M, Fry N, Mathee K, Trujillo ME, Bentley S, Thomson N.

J Med Microbiol. 2019 Feb;68(2):117-118. doi: 10.1099/jmm.0.000887. Epub 2018 Dec 5. No abstract available.

PMID:
30516466
14.

DORA Editorial.

Parish T, Harris M, Fry N, Mathee K, Trujillo ME, Bentley S, Thomson N.

Microb Genom. 2018 Dec;4(12). doi: 10.1099/mgen.0.000238. Epub 2018 Dec 5. No abstract available.

15.

DORA Editorial.

Parish T, Harris M, Fry N, Mathee K, Trujillo ME, Bentley S, Thomson N.

Int J Syst Evol Microbiol. 2019 Jan;69(1):1-2. doi: 10.1099/ijsem.0.003172. No abstract available.

PMID:
30516461
16.

Steps to address anti-microbial drug resistance in today's drug discovery.

Parish T.

Expert Opin Drug Discov. 2019 Feb;14(2):91-94. doi: 10.1080/17460441.2019.1550481. Epub 2018 Nov 22. No abstract available.

PMID:
30466326
17.

Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA.

Xia Y, Zhou Y, Carter DS, McNeil MB, Choi W, Halladay J, Berry PW, Mao W, Hernandez V, O'Malley T, Korkegian A, Sunde B, Flint L, Woolhiser LK, Scherman MS, Gruppo V, Hastings C, Robertson GT, Ioerger TR, Sacchettini J, Tonge PJ, Lenaerts AJ, Parish T, Alley M.

Life Sci Alliance. 2018 Jun 1;1(3):e201800025. doi: 10.26508/lsa.201800025. eCollection 2018 Jun.

18.

Identification of Enolase as the Target of 2-Aminothiazoles in Mycobacterium tuberculosis.

Wescott HH, Zuniga ES, Bajpai A, Trujillo C, Ehrt S, Schnappinger D, Roberts DM, Parish T.

Front Microbiol. 2018 Oct 26;9:2542. doi: 10.3389/fmicb.2018.02542. eCollection 2018.

19.

Novel Screen to Assess Bactericidal Activity of Compounds Against Non-replicating Mycobacterium abscessus.

Berube BJ, Castro L, Russell D, Ovechkina Y, Parish T.

Front Microbiol. 2018 Oct 10;9:2417. doi: 10.3389/fmicb.2018.02417. eCollection 2018.

20.

A class of hydrazones are active against non-replicating Mycobacterium tuberculosis.

Bonnett SA, Dennison D, Files M, Bajpai A, Parish T.

PLoS One. 2018 Oct 17;13(10):e0198059. doi: 10.1371/journal.pone.0198059. eCollection 2018.

21.

Activation of 2,4-Diaminoquinazoline in Mycobacterium tuberculosis by Rv3161c, a Putative Dioxygenase.

Melief E, Bonnett SA, Zuniga ES, Parish T.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01505-18. doi: 10.1128/AAC.01505-18. Print 2019 Jan.

22.

Codon-optimized DsRed fluorescent protein for use in Mycobacterium tuberculosis.

Carroll P, Muwanguzi-Karugaba J, Parish T.

BMC Res Notes. 2018 Oct 1;11(1):685. doi: 10.1186/s13104-018-3798-3.

23.

Construction of an overexpression library for Mycobacterium tuberculosis.

Melief E, Kokoczka R, Files M, Bailey MA, Alling T, Li H, Ahn J, Misquith A, Korkegian A, Roberts D, Sacchettini J, Parish T.

Biol Methods Protoc. 2018;3(1):bpy009. doi: 10.1093/biomethods/bpy009. Epub 2018 Aug 20.

24.

In Vitro Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium tuberculosis.

Odingo J, Bailey MA, Files M, Early JV, Alling T, Dennison D, Bowman J, Dalai S, Kumar N, Cramer J, Masquelin T, Hipskind PA, Parish T.

ACS Omega. 2017 Sep 30;2(9):5873-5890. doi: 10.1021/acsomega.7b00892. Epub 2017 Sep 18.

25.

Identification of cyclic hexapeptides natural products with inhibitory potency against Mycobacterium tuberculosis.

Singh SB, Odingo J, Bailey MA, Sunde B, Korkegian A, O'Malley T, Ovechkina Y, Ioerger TR, Sacchettini JC, Young K, Olsen DB, Parish T.

BMC Res Notes. 2018 Jun 28;11(1):416. doi: 10.1186/s13104-018-3526-z.

26.

High content, high-throughput screening for small molecule inducers of NF-κB translocation.

Njikan S, Manning AJ, Ovechkina Y, Awasthi D, Parish T.

PLoS One. 2018 Jun 28;13(6):e0199966. doi: 10.1371/journal.pone.0199966. eCollection 2018.

27.

Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.

Cleghorn LAT, Ray PC, Odingo J, Kumar A, Wescott H, Korkegian A, Masquelin T, Lopez Moure A, Wilson C, Davis S, Huggett M, Turner P, Smith A, Epemolu O, Zuccotto F, Riley J, Scullion P, Shishikura Y, Ferguson L, Rullas J, Guijarro L, Read KD, Green SR, Hipskind P, Parish T, Wyatt PG.

J Med Chem. 2018 Aug 9;61(15):6592-6608. doi: 10.1021/acs.jmedchem.8b00172. Epub 2018 Jul 26.

28.

Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of Mycobacterium tuberculosis.

Martinez-Grau MA, Valcarcel ICG, Early JV, Gessner RK, de Melo CS, de la Nava EMM, Korkegian A, Ovechkina Y, Flint L, Gravelle A, Cramer JW, Desai PV, Street LJ, Odingo J, Masquelin T, Chibale K, Parish T.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1758-1764. doi: 10.1016/j.bmcl.2018.04.028. Epub 2018 Apr 13.

29.

Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels.

O'Malley T, Alling T, Early JV, Wescott HA, Kumar A, Moraski GC, Miller MJ, Masquelin T, Hipskind PA, Parish T.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02439-17. doi: 10.1128/AAC.02439-17. Print 2018 Jun.

30.

The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis.

Korkegian A, O'Malley T, Xia Y, Zhou Y, Carter DS, Sunde B, Flint L, Thompson D, Ioerger TR, Sacchettini J, Alley MRK, Parish T.

Tuberculosis (Edinb). 2018 Jan;108:96-98. doi: 10.1016/j.tube.2017.11.003. Epub 2017 Nov 7.

31.

Microbe Profile: Mycobacterium tuberculosis: Humanity's deadly microbial foe.

Gordon SV, Parish T.

Microbiology. 2018 Apr;164(4):437-439. doi: 10.1099/mic.0.000601. Epub 2018 Feb 21.

PMID:
29465344
32.

Corrigendum to "Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA" [Tuberculosis 107 (December 2017) 133-136].

McNeil MB, Dennison D, Shelton C, Flint L, Korkegian A, Parish T.

Tuberculosis (Edinb). 2018 May;110:123. doi: 10.1016/j.tube.2018.02.001. Epub 2018 Feb 21. No abstract available.

PMID:
29429955
33.

Combinations of Respiratory Chain Inhibitors Have Enhanced Bactericidal Activity against Mycobacterium tuberculosis.

Berube BJ, Parish T.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01677-17. doi: 10.1128/AAC.01677-17. Print 2018 Jan.

34.

Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA.

McNeil MB, Dennison D, Shelton C, Flint L, Korkegian A, Parish T.

Tuberculosis (Edinb). 2017 Dec;107:133-136. doi: 10.1016/j.tube.2017.09.003. Epub 2017 Sep 13. Erratum in: Tuberculosis (Edinb). 2018 Feb 8;:.

35.

Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB.

Chandrasekera NS, Berube BJ, Shetye G, Chettiar S, O'Malley T, Manning A, Flint L, Awasthi D, Ioerger TR, Sacchettini J, Masquelin T, Hipskind PA, Odingo J, Parish T.

ACS Infect Dis. 2017 Dec 8;3(12):898-916. doi: 10.1021/acsinfecdis.7b00112. Epub 2017 Oct 31.

36.

Nitazoxanide is active against Mycobacterium leprae.

Bailey MA, Na H, Duthie MS, Gillis TP, Lahiri R, Parish T.

PLoS One. 2017 Aug 29;12(8):e0184107. doi: 10.1371/journal.pone.0184107. eCollection 2017.

37.

In Vitro Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis.

McNeil MB, Dennison DD, Shelton CD, Parish T.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01296-17. doi: 10.1128/AAC.01296-17. Print 2017 Oct.

38.

Mutations in MmpL3 alter membrane potential, hydrophobicity and antibiotic susceptibility in Mycobacterium smegmatis.

McNeil MB, Dennison D, Parish T.

Microbiology. 2017 Jul;163(7):1065-1070. doi: 10.1099/mic.0.000498. Epub 2017 Jul 21.

PMID:
28703701
39.

A Novel 6-Benzyl Ether Benzoxaborole Is Active against Mycobacterium tuberculosis In Vitro.

Patel N, O'Malley T, Zhang YK, Xia Y, Sunde B, Flint L, Korkegian A, Ioerger TR, Sacchettini J, Alley MRK, Parish T.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01205-17. doi: 10.1128/AAC.01205-17. Print 2017 Sep.

40.

The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents.

Zuniga ES, Korkegian A, Mullen S, Hembre EJ, Ornstein PL, Cortez G, Biswas K, Kumar N, Cramer J, Masquelin T, Hipskind PA, Odingo J, Parish T.

Bioorg Med Chem. 2017 Aug 1;25(15):3922-3946. doi: 10.1016/j.bmc.2017.05.030. Epub 2017 May 19.

41.

A high content microscopy assay to determine drug activity against intracellular Mycobacterium tuberculosis.

Manning AJ, Ovechkina Y, McGillivray A, Flint L, Roberts DM, Parish T.

Methods. 2017 Aug 15;127:3-11. doi: 10.1016/j.ymeth.2017.03.022. Epub 2017 Mar 31.

42.

Imidazoles Induce Reactive Oxygen Species in Mycobacterium tuberculosis Which Is Not Associated with Cell Death.

Howell Wescott HA, Roberts DM, Allebach CL, Kokoczka R, Parish T.

ACS Omega. 2017 Jan 31;2(1):41-51. doi: 10.1021/acsomega.6b00212. Epub 2017 Jan 5.

43.

Antituberculosis drugs: reducing efflux=increasing activity.

Rodrigues L, Parish T, Balganesh M, Ainsa JA.

Drug Discov Today. 2017 Mar;22(3):592-599. doi: 10.1016/j.drudis.2017.01.002. Epub 2017 Jan 13. Review.

PMID:
28089787
44.

Mycobacterium tuberculosis Rv0560c is not essential for growth in vitro or in macrophages.

Kokoczka R, Schuessler DL, Early JV, Parish T.

Tuberculosis (Edinb). 2017 Jan;102:3-7. doi: 10.1016/j.tube.2016.11.001. Epub 2016 Nov 5.

45.

Current challenges in drug discovery for tuberculosis.

Kumar A, Chettiar S, Parish T.

Expert Opin Drug Discov. 2017 Jan;12(1):1-4. Epub 2016 Nov 11. No abstract available.

PMID:
27797593
46.

A Target-Based Whole Cell Screen Approach To Identify Potential Inhibitors of Mycobacterium tuberculosis Signal Peptidase.

Bonnett SA, Ollinger J, Chandrasekera S, Florio S, O'Malley T, Files M, Jee JA, Ahn J, Casey A, Ovechkina Y, Roberts D, Korkegian A, Parish T.

ACS Infect Dis. 2016 Dec 9;2(12):893-902. Epub 2016 Sep 19.

47.

Micrococcin P1 - A bactericidal thiopeptide active against Mycobacterium tuberculosis.

Degiacomi G, Personne Y, Mondésert G, Ge X, Mandava CS, Hartkoorn RC, Boldrin F, Goel P, Peisker K, Benjak A, Barrio MB, Ventura M, Brown AC, Leblanc V, Bauer A, Sanyal S, Cole ST, Lagrange S, Parish T, Manganelli R.

Tuberculosis (Edinb). 2016 Sep;100:95-101. doi: 10.1016/j.tube.2016.07.011. Epub 2016 Jul 27.

PMID:
27553416
48.

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.

Palencia A, Li X, Bu W, Choi W, Ding CZ, Easom EE, Feng L, Hernandez V, Houston P, Liu L, Meewan M, Mohan M, Rock FL, Sexton H, Zhang S, Zhou Y, Wan B, Wang Y, Franzblau SG, Woolhiser L, Gruppo V, Lenaerts AJ, O'Malley T, Parish T, Cooper CB, Waters MG, Ma Z, Ioerger TR, Sacchettini JC, Rullas J, Angulo-Barturen I, Pérez-Herrán E, Mendoza A, Barros D, Cusack S, Plattner JJ, Alley MR.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6271-80. doi: 10.1128/AAC.01339-16. Print 2016 Oct.

49.

Synthesis and Evaluation of the 2-Aminothiazoles as Anti-Tubercular Agents.

Kesicki EA, Bailey MA, Ovechkina Y, Early JV, Alling T, Bowman J, Zuniga ES, Dalai S, Kumar N, Masquelin T, Hipskind PA, Odingo JO, Parish T.

PLoS One. 2016 May 12;11(5):e0155209. doi: 10.1371/journal.pone.0155209. eCollection 2016.

50.

Synergy between Colistin and the Signal Peptidase Inhibitor MD3 Is Dependent on the Mechanism of Colistin Resistance in Acinetobacter baumannii.

Martínez-Guitián M, Vázquez-Ucha JC, Odingo J, Parish T, Poza M, Waite RD, Bou G, Wareham DW, Beceiro A.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4375-9. doi: 10.1128/AAC.00510-16. Print 2016 Jul.

Supplemental Content

Loading ...
Support Center